For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...
A natural antibacterial molecule shows clinical promise. Its unusual binding site is on an excellent target: ...
The pathogen C. diff—the most common cause of health care-associated infectious diarrhea—can use a compound that kills the ...
Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...
Mouse cells tweaked to produce the tardigrade protein incurred less DNA damage than unaltered cells — hinting at a new tool for cancer patient care.
A study focusing on analyzing cell models found universality in their movement—an important discovery that could impact both ...
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
New research sheds light on one of the biggest questions in biology: where did complex life come from? The answer may lie ...
A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...
B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback